36 results
8-K
EX-3.1
ZNTL
Zentalis Pharmaceuticals Inc
15 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:12pm
or understanding with, and has not given and will not give any commitment or assurance to, any person or entity as to how such proposed nominee, if elected … as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) or (2) any Voting Commitment that could limit or interfere
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
8 Jan 24
Regulation FD Disclosure
7:03am
royalties.
“Immunome’s leadership team’s track record of advancing paradigm-changing ADCs, along with Zentalis’ commitment to apply cutting-edge
8-K
EX-99.1
55c3lvdu7p44ar5z
10 May 23
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
7:04am
8-K
EX-99.2
zm0m t6wut
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am
8-K
EX-99.2
0v52 gf2y4ge2
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am
8-K
EX-99.1
m03rpr t9pen
9 Aug 22
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
12:00am
8-K
EX-99.1
bg37f nun
27 Apr 22
Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer
4:09pm
10-K
9lttgc3v
25 Mar 21
Annual report
7:17am
8-K
EX-3.1
u1thc1wqp c9g9p
19 Mar 21
Amendments to Articles of Incorporation or Bylaws
4:08pm
DRS
EX-10.18
n1e9v
10 Jul 20
Draft registration statement
12:00am